|
|
|
|
| LEADER |
02212nmm a2200265 u 4500 |
| 001 |
EB002019292 |
| 003 |
EBX01000000000000001182190 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220804 ||| eng |
| 020 |
|
|
|a 9789811926150
|
| 100 |
1 |
|
|a Qi, Xingshun
|e [editor]
|
| 245 |
0 |
0 |
|a Pharmacotherapy for Liver Cirrhosis and Its Complications
|h Elektronische Ressource
|c edited by Xingshun Qi, Yongping Yang
|
| 250 |
|
|
|a 1st ed. 2022
|
| 260 |
|
|
|a Singapore
|b Springer Nature Singapore
|c 2022, 2022
|
| 300 |
|
|
|a XII, 240 p. 20 illus., 16 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Anti-HBV drugs in liver cirrhosis -- Anti-HCV drugs in liver cirrhosis -- Anticoagulants in liver cirrhosis -- Antibiotics in liver cirrhosis -- Silymarin in liver cirrhosis -- Ursodeoxycholic acid in liver cirrhosis -- Emricasan in liver cirrhosis -- Non-selective beta blockers in liver cirrhosis -- Somatostatin and octreotide in liver cirrhosis -- Terlipressin in liver cirrhosis -- Diuretics in liver cirrhosis -- Statins in liver cirrhosis -- L-Ornithine L-Aspartate in liver cirrhosis -- Lactulose in liver cirrhosis
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Internal Medicine
|
| 700 |
1 |
|
|a Yang, Yongping
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-19-2615-0?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616
|
| 520 |
|
|
|a This book aims to provide an updated information on different types of major and emerging drugs for managing liver cirrhosis and its complications, including acute gastroesophageal variceal bleeding, ascites, hepatic encephalopathy, liver failure, acute kidney injury, and portal venous thrombosis. The chapters are organized by drug class, such as anti-HBV drugs, anti-HCV drugs, anticoagulants, and antibiotics, etc. The clinical efficacy, indication, and contra-indication of the various drug therapies are discussed using supportive reference material from authoritative sources and published clinical trials. It will be an invaluable reference for physicians who are treating patients with liver cirrhosis, especially those presenting with acute life-threatening complications
|